Clinical Trial

IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION

Study acronym: IMPReSSION
Recruiting
View on ClinicalTrials.gov →
Summary
Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-06-22; most recent amendment 2026-01-02.
Status change: Active, Not Recruiting → Recruiting 2026-01-02
Status change: Recruiting → Active, Not Recruiting 2022-12-13
Trial Details
NCT Number NCT04444128
Lead Sponsor Johann Wolfgang Goethe University Hospital
Conditions Myocarditis, Heart Failure, Myocardial Fibrosis, Vascular Inflammation, Long COVID Syndrome
Enrollment 6,000 participants
Start Date 2016-11-15
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-06